
Louise J Longworth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8383964/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores. Applied Health Economics and Health Policy, 2022, 20, 119-131.	2.1	3
2	Effect of post-operative goal-directed fluid therapy (GDFT) on organ function after orthotopic liver transplantation: Secondary outcome analysis of the COLT randomised control trial. International Journal of Surgery, 2022, 99, 106265.	2.7	2
3	An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib. Value in Health, 2022, , .	0.3	2
4	Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. European Journal of Health Economics, 2021, 22, 1301-1309.	2.8	3
5	Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities. PharmacoEconomics - Open, 2021, 5, 715-725.	1.8	1
6	Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study. European Journal of Cancer, Supplement, 2021, 16, 14-23.	2.2	2
7	The cardiac output optimisation following liver transplant (COLT) trial: a feasibility randomised controlled trial. Hpb, 2020, 22, 1112-1120.	0.3	7
8	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. European Journal of Health Economics, 2020, 21, 1421-1437.	2.8	38
9	Referral pathways for patients with NAFLD based on nonâ€invasive fibrosis tests: Diagnostic accuracy and cost analysis. Liver International, 2019, 39, 2052-2060.	3.9	49
10	Elicitation of Health-Related Utility in Perianal Fistula in Crohn's Disease. Patient, 2019, 12, 339-348.	2.7	5
11	How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?. Medical Decision Making, 2018, 38, 306-318.	2.4	9
12	Views of the UK General Public on Important Aspects of Health Not Captured by EQ-5D. Patient, 2017, 10, 701-709.	2.7	21
13	COMPARISON OF METHODS FOR ESTIMATING CONTEMPORARY COSTS: AN APPLICATION TO LIVER TRANSPLANTATION IN THE UNITED KINGDOM. International Journal of Technology Assessment in Health Care, 2017, 33, 620-628.	0.5	0
14	The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax, 2016, 71, 493-500.	5.6	196
15	An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies. Value in Health, 2016, 19, 53-59.	0.3	14
16	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. Value in Health, 2016, 19, 885-891.	0.3	38
17	Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?. Value in Health, 2016, 19, 210-217.	0.3	21
18	Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Quality of Life Research, 2016, 25, 275-281.	3.1	14

LOUISE J LONGWORTH

#	Article	IF	CITATIONS
19	PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT. International Journal of Technology Assessment in Health Care, 2015, 31, 230-235.	0.5	7
20	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Medical Decision Making, 2015, 35, NP1-NP8.	2.4	1
21	Mapping Functions in Health-Related Quality of Life. Medical Decision Making, 2015, 35, 912-926.	2.4	35
22	The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration. Pharmacoeconomics, 2015, 33, 993-1011.	3.3	70
23	EQ-5D in skin conditions: an assessment of validity and responsiveness. European Journal of Health Economics, 2015, 16, 927-939.	2.8	66
24	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Applied Health Economics and Health Policy, 2015, 13, 437-443.	2.1	1
25	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. Health and Quality of Life Outcomes, 2015, 13, 106.	2.4	13
26	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Pharmacoeconomics, 2015, 33, 985-991.	3.3	21
27	The Debrisoft® Monofilament Debridement Pad for Use in Acute or Chronic Wounds: A NICE Medical Technology Guidance. Applied Health Economics and Health Policy, 2015, 13, 583-594.	2.1	17
28	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. Journal of Medical Economics, 2015, 18, 851-857.	2.1	4
29	An Exploratory Study to Test the Impact on Three "Bolt-On―Items to the EQ-5D. Value in Health, 2015, 18, 52-60.	0.3	74
30	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-410.	2.8	130
31	Mapping the FACT-P to the Preference-Based EQ-5D Questionnaire in Metastatic Castration-Resistant Prostate Cancer. Value in Health, 2014, 17, 238-244.	0.3	21
32	Cost-effectiveness of upcoming treatments for hepatitis C: We need to get the models right. Journal of Hepatology, 2014, 61, 453-454.	3.7	2
33	Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology, 2014, 60, 832-843.	7.3	59
34	Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technology Assessment, 2014, 18, 1-224.	2.8	276
35	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. Health Technology Assessment, 2014, 18, vii-xxvi, 1-191.	2.8	47
36	An assessment of validity and responsiveness of generic measures of health-related quality of life in hearing impairment. Quality of Life Research, 2013, 22, 2813-2828.	3.1	38

LOUISE J LONGWORTH

#	Article	IF	CITATIONS
37	Evaluation of content on EQ-5D as compared to disease-specific utility measures. Quality of Life Research, 2013, 22, 853-874.	3.1	26
38	When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?. Pharmacoeconomics, 2013, 31, 137-149.	3.3	18
39	Mapping to Obtain EQ-5D Utility Values for Use in NICE Health Technology Assessments. Value in Health, 2013, 16, 202-210.	0.3	202
40	Exploring what lies behind public preferences for avoiding health losses caused by lapses in healthcare safety and patient lifestyle choices. BMC Health Services Research, 2013, 13, 249.	2.2	0
41	Binary Choice Health State Valuation and Mode of Administration: Head-to-Head Comparison of Online and CAPI. Value in Health, 2013, 16, 104-113.	0.3	61
42	A Review of Generic Preference-Based Measures of Health-Related Quality of Life in Visual Disorders. Value in Health, 2012, 15, 118-127.	0.3	112
43	Does Responsibility Affect the Public's Valuation of Health Care Interventions? A Relative Valuation Approach to Health Care Safety. Value in Health, 2012, 15, 690-698.	0.3	9
44	Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value in Health, 2011, 14, 102-109.	0.3	70
45	Bridging the gap between methods research and the needs of policy makers: A review of the research priorities of the National Institute for Health and Clinical Excellence. International Journal of Technology Assessment in Health Care, 2011, 27, 180-187.	0.5	13
46	NICE Methodology for Technology Appraisals. Pharmacoeconomics, 2008, 26, 729-732.	3.3	9
47	An Economic Evaluation of Pediatric Small Bowel Transplantation in the United Kingdom. Transplantation, 2006, 82, 508-515.	1.0	11
48	Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. British Journal of Psychiatry, 2006, 188, 337-345.	2.8	36
49	An Assessment of the Impact of Informative Dropout and Nonresponse in Measuring Health-Related Quality of Life Using the EuroQol (EQ-5D) Descriptive System. Value in Health, 2005, 8, 53-58.	0.3	15
50	Measuring health-related utility:. European Journal of Health Economics, 2005, 6, 253-260.	2.8	63
51	Comparison of general practitioner records and patient self-report questionnaires for estimation of costs. European Journal of Health Economics, 2005, 6, 261-266.	2.8	22
52	Estimating utility data from clinical indicators for patients with stable angina. European Journal of Health Economics, 2005, 6, 347-353.	2.8	51
53	Determining Priority for Liver Transplantation. Applied Health Economics and Health Policy, 2005, 4, 249-255.	2.1	22
54	Women and health care professionals' preferences for Down's Syndrome screening tests: a conjoint analysis study. BJOG: an International Journal of Obstetrics and Gynaecology, 2004, 111, 775-779.	2.3	83

#	Article	IF	CITATIONS
55	An empirical comparison of EQâ€5D and SFâ€6D in liver transplant patients. Health Economics (United) Tj ETQq1	1,0.78431 1.7	.4 rgBT /Ov∉
56	Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transplantation, 2003, 9, 1295-1307.	2.4	70
57	Survival gain after liver transplantation for patients with alcoholic liver disease: a comparison across models and centers. Transplantation, 2003, 76, 1479-1486.	1.0	6
58	Assessing health-related quality of life pre[ndash] and post[ndash]liver transplantation: A prospective multicenter study. Liver Transplantation, 2002, 8, 263-270.	2.4	131
59	Investigating women's preferences for intrapartum care: home versus hospital births. Health and Social Care in the Community, 2001, 9, 404-413.	1.6	59